JPH01297069A - Tacky adhesive agent composition - Google Patents
Tacky adhesive agent compositionInfo
- Publication number
- JPH01297069A JPH01297069A JP63129387A JP12938788A JPH01297069A JP H01297069 A JPH01297069 A JP H01297069A JP 63129387 A JP63129387 A JP 63129387A JP 12938788 A JP12938788 A JP 12938788A JP H01297069 A JPH01297069 A JP H01297069A
- Authority
- JP
- Japan
- Prior art keywords
- parts
- block copolymer
- water
- polymer
- pts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000853 adhesive Substances 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims description 31
- 229920005989 resin Polymers 0.000 claims abstract description 21
- 239000011347 resin Substances 0.000 claims abstract description 21
- 229920000642 polymer Polymers 0.000 claims abstract description 18
- 239000003208 petroleum Substances 0.000 claims abstract description 17
- 229920000428 triblock copolymer Polymers 0.000 claims abstract description 16
- 125000002723 alicyclic group Chemical group 0.000 claims abstract description 13
- 230000001070 adhesive effect Effects 0.000 claims description 34
- -1 polyethylene Polymers 0.000 abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 12
- 238000002156 mixing Methods 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 239000004698 Polyethylene Substances 0.000 abstract description 3
- 229920001400 block copolymer Polymers 0.000 abstract description 3
- 229920000573 polyethylene Polymers 0.000 abstract description 3
- 229920003169 water-soluble polymer Polymers 0.000 abstract description 3
- 229920001577 copolymer Polymers 0.000 abstract description 2
- 238000004132 cross linking Methods 0.000 abstract description 2
- 125000006841 cyclic skeleton Chemical group 0.000 abstract description 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 2
- 229920001971 elastomer Polymers 0.000 abstract description 2
- 229930195729 fatty acid Natural products 0.000 abstract description 2
- 239000000194 fatty acid Substances 0.000 abstract description 2
- 150000004665 fatty acids Chemical class 0.000 abstract description 2
- 239000002480 mineral oil Substances 0.000 abstract description 2
- 235000010446 mineral oil Nutrition 0.000 abstract description 2
- 239000005060 rubber Substances 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract 1
- 210000004243 sweat Anatomy 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 206010040880 Skin irritation Diseases 0.000 description 8
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 230000036556 skin irritation Effects 0.000 description 8
- 231100000475 skin irritation Toxicity 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- NPERTKSDHFSDLC-UHFFFAOYSA-N ethenol;prop-2-enoic acid Chemical compound OC=C.OC(=O)C=C NPERTKSDHFSDLC-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000123 paper Substances 0.000 description 5
- 239000004902 Softening Agent Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 229960001047 methyl salicylate Drugs 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960002389 glycol salicylate Drugs 0.000 description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
- 229960000991 ketoprofen Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 235000019477 peppermint oil Nutrition 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000005062 Polybutadiene Substances 0.000 description 2
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 229950002568 bucumolol Drugs 0.000 description 2
- CIJVBYRUFLGDHY-UHFFFAOYSA-N bucumolol Chemical compound O1C(=O)C=CC2=C1C(OCC(O)CNC(C)(C)C)=CC=C2C CIJVBYRUFLGDHY-UHFFFAOYSA-N 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229960004930 fludiazepam Drugs 0.000 description 2
- ROYOYTLGDLIGBX-UHFFFAOYSA-N fludiazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ROYOYTLGDLIGBX-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229960002508 pindolol Drugs 0.000 description 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920002857 polybutadiene Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 229960004856 prazepam Drugs 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- UHSXRTHJCJGEKG-UQKRIMTDSA-N (1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-6,7-diol;chloride Chemical compound Cl.COC1=C(OC)C(OC)=CC(C[C@H]2C3=CC(O)=C(O)C=C3CCN2)=C1 UHSXRTHJCJGEKG-UQKRIMTDSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- BFUXUGOZJVHVMR-UHFFFAOYSA-N 1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1CNS(=O)(=O)C2=CC(S(=O)(=O)N)=CC=C21 BFUXUGOZJVHVMR-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001566735 Archon Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920004939 Cariflex™ Polymers 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 description 1
- ZVXBAHLOGZCFTP-UHFFFAOYSA-N Efloxate Chemical compound C=1C(OCC(=O)OCC)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZVXBAHLOGZCFTP-UHFFFAOYSA-N 0.000 description 1
- URJQOOISAKEBKW-UHFFFAOYSA-N Emorfazone Chemical compound C1=NN(C)C(=O)C(OCC)=C1N1CCOCC1 URJQOOISAKEBKW-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- WMFSSTNVXWNLKI-UHFFFAOYSA-N Flutazolam Chemical compound O1CCN2CC(=O)N(CCO)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1F WMFSSTNVXWNLKI-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- RSLNRVYIRDVHLY-UHFFFAOYSA-N Tulobuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC=CC=C1Cl RSLNRVYIRDVHLY-UHFFFAOYSA-N 0.000 description 1
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- 229960004335 azelastine hydrochloride Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229960002335 bromhexine hydrochloride Drugs 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 description 1
- 229960001399 clenbuterol hydrochloride Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003932 cloxazolam Drugs 0.000 description 1
- ZIXNZOBDFKSQTC-UHFFFAOYSA-N cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960003970 diflucortolone valerate Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- 229940099401 dimethindene maleate Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229960003859 efloxate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229950010243 emorfazone Drugs 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RFWTZQAOOLFXAY-BZDYCCQFSA-N estradiol enanthate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 RFWTZQAOOLFXAY-BZDYCCQFSA-N 0.000 description 1
- 229950004659 estradiol enanthate Drugs 0.000 description 1
- 229950007164 ethiazide Drugs 0.000 description 1
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 description 1
- UQXKXGWGFRWILX-UHFFFAOYSA-N ethylene glycol dinitrate Chemical compound O=N(=O)OCCON(=O)=O UQXKXGWGFRWILX-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229950009354 flutazolam Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 229950008838 indenolol Drugs 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960003739 methyclothiazide Drugs 0.000 description 1
- LZULAZTXJLWELL-UHFFFAOYSA-N methyl hex-5-ynoate Chemical compound COC(=O)CCCC#C LZULAZTXJLWELL-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960003746 metildigoxin Drugs 0.000 description 1
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- 229950000412 mexazolam Drugs 0.000 description 1
- ANUCDXCTICZJRH-UHFFFAOYSA-N mexazolam Chemical compound C=1C=C(Cl)C=C2C=1NC(=O)CN1C(C)COC21C1=CC=CC=C1Cl ANUCDXCTICZJRH-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229950001981 nimetazepam Drugs 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229950006124 oxazolam Drugs 0.000 description 1
- VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- BOFKYYWJAOZDPB-FZNHGJLXSA-N prednival Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O BOFKYYWJAOZDPB-FZNHGJLXSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960002789 procaterol hydrochloride Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960004846 tulobuterol hydrochloride Drugs 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229950010121 ufenamate Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は従来の医療用粘着剤の持つ欠点を解消した新規
な粘着剤組成物を提供することにある。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The object of the present invention is to provide a novel adhesive composition that overcomes the drawbacks of conventional medical adhesives.
従来より、手術用ドレッシング、絆創膏、テーピング等
の粘着テープ、又薬物を経皮より投与する手段としての
プラスター、テープ剤、パッチ、パップ剤等に粘着剤が
用いられてきた。しかし、これらの粘着剤はその使用に
あたり、剥離時の毛の引張り、粘着剤の硬さによる皮膚
の圧迫、皮膚の動きと粘着剤のズレ等による擦過、及び
通気性、透湿性がなく、これを皮膚に貼付した場合、皮
膚表面の杼口閉塞を引き起こし、水分の拡散が止まって
しまい、汗や分泌物に含まれる刺激成分により気触れが
発生している。BACKGROUND ART Adhesives have heretofore been used in adhesive tapes such as surgical dressings, adhesive plasters, and tapings, as well as plasters, tapes, patches, poultices, etc. as means for transdermally administering drugs. However, when using these adhesives, there are problems such as hair pulling when peeled off, pressure on the skin due to the hardness of the adhesive, abrasion due to movement of the skin and slippage of the adhesive, and lack of breathability and moisture permeability. When applied to the skin, it causes a blockage of the skin surface, stopping the diffusion of moisture, and causing irritation due to the irritating components contained in sweat and secretions.
一方、これらの問題を解決する手段として種々の試みが
なされている。On the other hand, various attempts have been made to solve these problems.
例えば、特公昭58−52251号には膏体に通気孔を
あける方法が提示されている。又特開昭58−4721
号、特開昭60−56911号、特開昭60−2331
2号等には気触れ防止あるいは皮膚刺激低減のための薬
物配合が示されている。特開昭60−75428には伸
縮性基布に特定の粘着剤で用いたものが示されている。For example, Japanese Patent Publication No. 58-52251 proposes a method of making ventilation holes in plaster. Also, Japanese Patent Publication No. 58-4721
No., JP-A-60-56911, JP-A-60-2331
No. 2 etc. shows drug combinations to prevent exposure or reduce skin irritation. JP-A-60-75428 discloses the use of a specific adhesive on a stretchable base fabric.
特公昭59−19528号には基剤に特殊な処理をほど
こし、皮膚刺激を低減させる方法が提示されている。し
かし、いずれの場合においても実用性に問題があったり
、製造工程が複雑であったり、又、その効果も不充分な
ものである。又、気触れの主たる原因である汗や分泌物
を基剤中に吸汗あるいは吸着させる方法も試みられてお
り、例えば、特公昭54−44688号ではPVAやセ
)Ltロース類を配合する方法、実開昭55−1925
8号では多ti類ガムを配合、特公昭58−23846
号及び特開昭60−41968号ではアクリル共重合体
を配合する方法が開示されている。又、特開昭60−1
23416号及び特開昭60−123417号では、水
溶性高分子及び多糖類を配合することによって貼付剤に
吸汗性あるいは水分透過性を付与し、皮膚刺激の低減が
試みられている。Japanese Patent Publication No. 59-19528 proposes a method of reducing skin irritation by subjecting the base material to special treatment. However, in either case, there are problems in practicality, the manufacturing process is complicated, and the effects are insufficient. In addition, methods have been attempted in which sweat and secretions, which are the main cause of skin irritation, are absorbed or adsorbed into the base.For example, in Japanese Patent Publication No. 54-44688, a method of blending PVA and Lt loins, Jitsukai 55-1925
No. 8 contains multi-tidal gum, Special Publication No. 58-23846
No. 60-41968 discloses a method of blending an acrylic copolymer. Also, JP-A-60-1
No. 23416 and JP-A-60-123417 attempt to reduce skin irritation by imparting sweat absorption or water permeability to patches by incorporating water-soluble polymers and polysaccharides.
しかしながら、実際上は、逆に水溶性であるがゆえに膏
体が汗で溶は出す場合もあり、更には、いずれの場合に
おいても吸水、吸汗能力としては不充分で、せいぜい1
〜1.0%程度の吸水能力でしかないために完全に汗あ
るいは分泌物を吸着しておらず、従って、吸着されなか
った汗や分泌物による気触れが発生している現状である
。However, in reality, since it is water-soluble, the plaster may dissolve with sweat, and in any case, the water and sweat absorption ability is insufficient, at most 1.
Since it has a water absorption capacity of only about 1.0%, it does not completely adsorb sweat or secretions, and therefore, the current situation is that sweat and secretions that are not adsorbed cause a feeling of discomfort.
以上の如(、種々の方法が試みられているにもかかわら
ず、実用的には程遠く、結局未だ気触れのない理想的な
外用貼付剤は出現していないのが現状である。Despite the various methods described above being attempted, they are far from practical, and at present no ideal external patch that does not cause discomfort has yet appeared.
本発明者らは、この様な状況に鑑み、
■剥離時の毛の引張りの解消
■皮膚の動きに追従しうる柔軟な粘着
■長時間貼付によるムレ、発汗等の生理的作用による皮
膚刺激の解消
等の医療用粘着剤の副作用を解消するため、鋭意研究を
重ねた結果、A−B−A型ブロック共重合体、軟化剤、
吸水高分子、及び脂環族系石油樹脂からなる粘着剤組成
物が皮膚の動きに充分に追従しうる柔軟な粘着特性、及
び皮膚を圧迫することのない柔らかい粘着特性を保持し
、且つ皮膚よりの汗、分泌物を吸収、吸着することによ
り、剥離時の毛の引張り、ムレ又は気触れ等の副作用を
著しく軽減できることを見い出し本発明を完成するに至
った。In view of these circumstances, the inventors of the present invention have developed the following solutions: ■ Elimination of hair tension during peeling ■ Flexible adhesive that can follow the movement of the skin ■ Prevention of skin irritation due to physiological effects such as stuffiness and sweating due to long-term application. In order to eliminate the side effects of medical adhesives, such as dehydration, we have developed an A-B-A type block copolymer, a softening agent,
The adhesive composition composed of a water-absorbing polymer and an alicyclic petroleum resin has flexible adhesive properties that can sufficiently follow the movements of the skin, and soft adhesive properties that do not put pressure on the skin. The present inventors have discovered that by absorbing and adsorbing the sweat and secretions of the skin, side effects such as hair pulling, stuffiness, or feeling when peeled can be significantly reduced, and the present invention has been completed.
本発明を構成する4つの要素について説明するが、どれ
が欠けても本発明を成さないものであり、各特定の成分
が本発明の必須要素である。The four elements constituting the present invention will be described, but the present invention does not exist even if any one is missing, and each specific component is an essential element of the present invention.
1)A−B−A型ブロック共重合体
本発明の粘着成分の主ポリマーであり保型性を持つもの
である。1) A-B-A type block copolymer This is the main polymer of the adhesive component of the present invention and has shape retention properties.
2)吸水高分子
本発明の粘着剤組成物にあって、皮膚よりの汗、分泌物
を、吸収、吸着するものである。2) Water-absorbing polymer The adhesive composition of the present invention absorbs and adsorbs sweat and secretions from the skin.
3)指環族系石油樹脂
粘着付与剤であり、A−B−A型ブロック共重合体との
組合せにより、初めて、最適の粘着特性が得られる。3) It is a ring-based petroleum resin tackifier, and optimal adhesive properties can only be obtained by combining it with an ABA type block copolymer.
4)軟化剤
A−B−A型ブロック共重合体を溶解し軟化させるもの
であり、A−B−A型ブロック共重合体と粘着付与樹脂
である脂環族系石油樹脂と軟化剤との組合せにより、本
発明の特徴である皮膚に追従する柔らかい物性、剥離時
の毛の引張りのない柔軟な粘着が発現するのである。4) Softener This is a material that dissolves and softens the A-B-A type block copolymer, and is a combination of the A-B-A type block copolymer, the alicyclic petroleum resin that is the tackifying resin, and the softener. This combination brings about the characteristics of the present invention: soft physical properties that follow the skin and soft adhesion that does not cause hair to pull when peeled off.
次に、各成分について詳しく説明する。Next, each component will be explained in detail.
A−B−A型ブロック共重合体とは、モノビニル置換芳
香族化合物Aと共役ジオレフィン共重合体Bとのブロッ
ク共重合体であり、具体的にはカリフレックスTR−1
101、カリフレックスTR−1107、カリフレ7ク
スTR−1111、カリフレックスTR−1112、カ
リフレックスTR−1117(シェル化学型)等、フィ
リップペトロリ・アム製のツルプレン418等であり、
その配合量は粘着剤組成中10〜30重量部であり、好
ましくは15〜25重量部である。The A-B-A type block copolymer is a block copolymer of monovinyl-substituted aromatic compound A and conjugated diolefin copolymer B, and specifically, Cariflex TR-1
101, Kaliflex TR-1107, Kaliflex 7x TR-1111, Kaliflex TR-1112, Kaliflex TR-1117 (Shell chemical type), etc., Turprene 418 manufactured by Philip Petroleum, etc.
The amount incorporated in the adhesive composition is 10 to 30 parts by weight, preferably 15 to 25 parts by weight.
吸水高分子とは、自重の10倍以上の水を吸収しゲル化
膨潤するものであり、例えば水溶性ポリマーに軽度な架
橋結合を導入した吸水高分子が、適宜単独もしくは2種
以上の混合でもって処方される。具体的には、サンウェ
ットIM−300、サンウェットIM−300MPS、
サンウェットIM−1000、サンウェットIM−10
00MPS(三洋化成製)等、アクアキープ4S、アク
アキープ4SH(製鉄化学製)等、スミカゲル5P−5
20、スミカゲルN−100,スミカゲルNP−102
0、スミカゲルNP−1040(住人化学製)等、Kl
ゲル201−に、KIゲル−201に−F2 (クラレ
製)等、アラソーブ800、アラソーブ800F (荒
用化学製)等であり、中でもサンウェットIM−300
MPS、サンウェットIM−1000MPS、スミカゲ
ルNP−1020、スミカゲルNP−1040、KIゲ
ル−201に−F2、アラソーブ800F等は特に好ま
しい。配合量としては、粘着剤組成物中1〜10重量部
であり、好ましくは2〜8重量部である。A water-absorbing polymer is one that absorbs more than 10 times its own weight of water and gels and swells. For example, a water-absorbing polymer that has a mild crosslinking bond introduced into a water-soluble polymer can be used alone or as a mixture of two or more. It is prescribed. Specifically, Sunwet IM-300, Sunwet IM-300MPS,
Sunwet IM-1000, Sunwet IM-10
00MPS (manufactured by Sanyo Chemical Co., Ltd.), Aqua Keep 4S, Aqua Keep 4SH (manufactured by Steel Chemical Co., Ltd.), etc., Sumikagel 5P-5
20, Sumikagel N-100, Sumikagel NP-102
0, Sumikagel NP-1040 (manufactured by Sumika Kagaku), etc., Kl
Gel 201-, KI Gel-201, -F2 (manufactured by Kuraray), Arasorb 800, Arasorb 800F (manufactured by Arayo Kagaku), etc. Among them, Sunwet IM-300
Particularly preferred are MPS, Sunwet IM-1000MPS, Sumikagel NP-1020, Sumikagel NP-1040, KI Gel-201-F2, Arasorb 800F, and the like. The blending amount is 1 to 10 parts by weight, preferably 2 to 8 parts by weight, in the pressure-sensitive adhesive composition.
脂環族系石油樹脂とは、環状骨格を持った石油系樹脂で
あり、具体的にはアルコンP−85、アルコンP−10
0、アルコンP−125(荒用化学製)等、エスコレッ
ツ3000 (エクソン製)等、フィントン(日本ゼオ
ン類)等であり、その配合量は10〜50重量部であり
、好ましくは、25〜45重量部である。Alicyclic petroleum resin is a petroleum resin with a cyclic skeleton, specifically Alcon P-85, Alcon P-10.
0, Alcon P-125 (manufactured by Arayo Kagaku), etc., Escoretz 3000 (manufactured by Exxon), Finton (Nippon Zeon), etc., and the blending amount is 10 to 50 parts by weight, preferably 25 to 45 parts by weight. Parts by weight.
軟化剤としては、高級脂肪酸、液状ゴム、鉱油等が用い
られ、その配合量としては、10〜50重量部、好まし
くは25〜45重量部である。As the softening agent, higher fatty acids, liquid rubber, mineral oil, etc. are used, and the amount thereof is 10 to 50 parts by weight, preferably 25 to 45 parts by weight.
その他使用目的に応じて、従来公知の老化防止剤、無機
充填剤、酸化防止剤等が適宜適量配合できる。In addition, conventionally known anti-aging agents, inorganic fillers, antioxidants, etc. can be added in appropriate amounts depending on the purpose of use.
以上のようにして、得られた本発明の粘着剤組成物は教
急絆創膏、手術後の傷口保護を目的としたサージカルド
レッシング、切開縫合部の補強固定用テープ、更にはス
ポーツ時に用いられるテーピング等にも利用可能である
。As described above, the adhesive composition of the present invention obtained can be used for Kyocera bandages, surgical dressings for the purpose of protecting wounds after surgery, tapes for reinforcing and fixing incisions and sutures, and even tapings used during sports. It is also available.
又、経皮吸収製薬物を含有させ医療用貼付剤として用い
ることができる。例えば、皮膚刺激剤及び鎮痛消炎剤と
して、サリチル酸、サリチル酸メチル、サリチル酸グリ
コール、l−メントール、カンフル、ハツカ油、チモー
ル、ニコチン酸ベンジルエステル、トウガラシエキス、
カブサイシン、ノニル酸ワニアルアミド、フルビナク、
フルフェナム酸ブチル、ピロキシカム、インドメタシン
、ケトプロフェン、プラノプロフェン、フエプラゾン、
ロキソブロフエン、アンツェナフナトリウム、オキサプ
ロジン、エモルファゾン、フェンチアザツク、ジクロツ
ェナフナトリウム、ジフルニサール、イブプロフェンピ
コノール、ペンダザック、及びスブロフェン、並びにこ
れらのエステル誘導体、あるいは塩酸ブプレノルフィン
、ペンタゾシン、酒石酸ブトルファノール等。Furthermore, it can be used as a medical patch by containing a drug for transdermal absorption. For example, as skin irritants and analgesic anti-inflammatory agents, salicylic acid, methyl salicylate, glycol salicylate, l-menthol, camphor, pepper oil, thymol, nicotinic acid benzyl ester, capsicum extract,
Kabsaicin, nonylic acid vanialamide, flubinac,
butyl flufenamate, piroxicam, indomethacin, ketoprofen, pranoprofen, fueprazone,
Loxobrofen, anzenaf sodium, oxaprozin, emorfazone, fentiazac, diclozenaf sodium, diflunisal, ibuprofenpiconol, pendazac, and subrofen, and their ester derivatives, or buprenorphine hydrochloride, pentazocine, butorphanol tartrate, etc.
中枢神経作用剤(睡眠鎮静剤、抗てんかん剤、精神神経
用剤)として、フルフェナジン、チオリダジン、ジアゼ
パム、クロルプロマジン、ニトラゼパム、エスタゾラム
、トリアゾラム、ニメタゼパム、フルジアゼパム、ハロ
セキサシラム、フルラゼパム、クロナゼパム、プロベリ
ジアジン、プロクロルペラジン、アルブラシラム、オキ
サゼパム、オキサゾラム、クロキサゾラム、プラゼパム
、フルタゾラム、メキサゾラム、ロラゼパム、フルジア
ゼパム、プロマゼバム、プラゼパム等。Central nervous system acting agents (sedative sleep agents, anti-epileptic agents, psychiatric agents) include fluphenazine, thioridazine, diazepam, chlorpromazine, nitrazepam, estazolam, triazolam, nimetazepam, fludiazepam, halosexacillam, flurazepam, clonazepam, proberidiazine, prochlor. Perazine, albrasulam, oxazepam, oxazolam, cloxazolam, prazepam, flutazolam, mexazolam, lorazepam, fludiazepam, promazebam, prazepam, etc.
利尿剤としてハイドロサイアザイド、ペンドロフルメチ
アジド、エチアジド、シクロペンチアジド、ヒドロクロ
ロチアジド、ペンフルチド、メチクロチアジド、フロセ
ミド、メトラゾン、ポリチアジド、ペンドロフルメチア
ジド等。Diuretics include hydrothiazide, pendroflumethiazide, ethiazide, cyclopenthiazide, hydrochlorothiazide, penflutide, methyclothiazide, furosemide, metolazone, polythiazide, pendroflumethiazide, etc.
血圧降下剤として、クロニジン、アルサーオキシロン、
レシナミン、メシル酸ジヒドロエルゴトキシン、レセル
、ピンプラゾシン、カプトプリル、ピンドロール、マレ
イン酸エナラプリル等。As antihypertensive agents, clonidine, altheroxirone,
Resinamine, dihydroergotoxin mesylate, Resel, pinprazosin, captopril, pindolol, enalapril maleate, etc.
冠血管拡張剤としてニトログリセリン、ニトログリコー
ル、イソソルバイトシナイトレート、塩酸バパペリン、
ジビリダモール、エフロキサート、トリメタシン、ニコ
ランジル、シンナリジン、ナイリドン、モルシドミンニ
フエジピン等。Coronary vasodilators include nitroglycerin, nitroglycol, isosorbite cinitrate, bapaperine hydrochloride,
Diviridamol, efloxate, trimetacin, nicorandil, cinnarizine, nyridone, molsidomine nifedipine, etc.
鎮咳去痰剤としてリン酸コデイン、リン酸ジヒドロコデ
イン、塩酸エフェドリン、塩酸クロルプレナリン、臭化
水素酸フェノチロール、硫酸サルブタモール、リン酸ジ
メモルファン、塩酸アゼラスチン、塩酸クレンブテロー
ル、塩酸ツロブテロール、塩酸トリメトキノール、塩酸
プロカテロール、塩酸ブロムヘキシン、トラニラスト、
ヒベンズ酸チペビジン、フマル酸ケトチフエン、フマル
酸フォルモチロール、リン酸ペンスプロペリン、グリチ
ルレチン酸等。As an antitussive expectorant: codeine phosphate, dihydrocodeine phosphate, ephedrine hydrochloride, chlorprenaline hydrochloride, phenotyrol hydrobromide, salbutamol sulfate, dimemorphan phosphate, azelastine hydrochloride, clenbuterol hydrochloride, tulobuterol hydrochloride, trimethoquinol hydrochloride, procaterol hydrochloride, Bromhexine hydrochloride, tranilast,
Tipevidine hibenzate, ketotifen fumarate, formotyol fumarate, pensproperine phosphate, glycyrrhetinic acid, etc.
抗ヒスタミン剤として塩酸ジフェンヒドラミン、塩酸ト
リプロリジン、塩酸イソチベンジル、塩酸プロメタシン
、マレイン酸クロルフェニラミン、塩酸シプロへブタジ
ン、フマル酸タレマスチン、マレイン酸カルビノキサミ
ン、マレイン酸ジメチンデン等。Antihistamines include diphenhydramine hydrochloride, triprolidine hydrochloride, isotibenzyl hydrochloride, promethacin hydrochloride, chlorpheniramine maleate, cyprohebutadine hydrochloride, talemastine fumarate, carbinoxamine maleate, dimethindene maleate, etc.
不整脈用剤としてアルプレノロール、オクスプレノロー
ル、ブクモロール、ブプラノロール、ピンドロール、イ
ンデノロール、カルテオロール、ブクモロール、プロプ
ラノロール、チモロール等。Arrhythmia agents include alprenolol, oxprenolol, bucumolol, bupranolol, pindolol, indenolol, carteolol, bucumolol, propranolol, timolol, etc.
強心剤としてジキタリス、ユビデカレノン、ジゴキシン
、メチルジゴキシン、デストラノシド等。Cardiotropes include digitalis, ubidecarenone, digoxin, methyldigoxin, and destranoside.
性ホルモンとしてエストラジオールエナンテート、エス
トラジオールシピネート、レボノルゲストレル、エスト
ラジオール等。Estradiol enanthate, estradiol cipinate, levonorgestrel, estradiol, etc. as sex hormones.
副腎皮膚ホルモン剤として酢酸ヒドロコルチゾン、ヒド
ロコルチゾン、プレドニゾロン、ドリアムシノロンアセ
トニド、デキサメタシンリン酸エステル、メチルプレド
ニゾロン、酢酸グイクロリンアセトニド、酢酸デキサメ
タシン、デキサメタシン、フルオロメトロン、リン酸ベ
タメタシンナトリウム、ベタメタシン、吉草酸ベタメタ
シン、プロピオン酸ベクロメタゾン、フルドロキシコル
チド、酪酸ヒドロコルチゾン、ジプロピオン酸ベタメタ
シン、フルオシノニド、プロピオン酸クロベタプール、
吉草酸ジフルコルトロン、ハルジノニド、アムシノニド
、吉草酸プレドニゾロン等。Adrenal skin hormones include hydrocortisone acetate, hydrocortisone, prednisolone, doriamcinolone acetonide, dexamethacin phosphate, methylprednisolone, gychlorine acetonide, dexamethacin acetate, dexamethacin, fluorometholone, betamethacin sodium phosphate, betamethacin, Betamethacin valerate, beclomethasone propionate, fludroxycortide, hydrocortisone butyrate, betamethacin dipropionate, fluocinonide, clobetapur propionate,
Diflucortolone valerate, haldinonide, amcinonide, prednisolone valerate, etc.
局所麻酔剤としてリドカイン、アミノ安息香酸エチル、
塩酸プロ力イン、ジブカイン、プロ力イン等が挙げられ
る。lidocaine, ethyl aminobenzoate, as a local anesthetic;
Examples include procytoin hydrochloride, dibucaine, procytoin, and the like.
これら薬効成分は、一種又は必要に応して二種以上配合
されて用いられる。These medicinal ingredients may be used alone or in combination of two or more if necessary.
支持体としては、例えばポリエチレン、ポリプロピレン
、ポリブタジェン、エチレン酢酸ビニル共重合体、ポリ
塩化ビニル、ポリエステル、ナイロン、ポリウレタン等
のフィルム又はシート、あるいはこれらの多孔体、発泡
体そして紙、布、不織布等の伸縮性又は非伸縮性の支持
体より選ばれる。Examples of the support include films or sheets of polyethylene, polypropylene, polybutadiene, ethylene vinyl acetate copolymer, polyvinyl chloride, polyester, nylon, polyurethane, or porous bodies and foams thereof, as well as paper, cloth, nonwoven fabric, etc. Selected from stretchable or non-stretchable supports.
次に、製造法としては、従来公知の方法で良く、例えば
、ニーダ−、ミキサー等の混練機を用い、120〜16
0℃程度の温度で混練し、テープあるいはシート基材に
直接展延するか、もしくはいったん剥離処理の施された
紙、フィルム等に展延し、その後使用する基材に圧着転
写して製造することもできる。Next, as a manufacturing method, a conventionally known method may be used, for example, using a kneader such as a kneader or a mixer,
It is manufactured by kneading it at a temperature of about 0°C and spreading it directly onto a tape or sheet substrate, or by spreading it onto paper, film, etc. that has been subjected to a release treatment, and then press-printing it onto the substrate to be used. You can also do that.
以上、上述した本発明の粘着剤組成物は、以下の試験例
、実施例で述べる如く、
1)A−B−A型ブロック共重合体10重量部〜30重
量部
2)吸水高分子1重量部〜10重量部
3)脂環族系石油樹脂10重量部〜50重量部4)軟化
剤10重量部〜50重量部
との組合せが必須であり、この特定の配合により■皮膚
に追従する柔らかい粘着特性
■汗、分泌物の吸収、及び吸着作用
等の特徴が発現し、常に皮膚に柔らかく付着し、剥離時
の毛の引張りもなく、更に、ムレ、発汗等による気触れ
の発生も抑えられた。正に理想的な粘着剤組成物となる
ものである。As mentioned above, the pressure-sensitive adhesive composition of the present invention described above, as described in the following test examples and examples, includes: 1) 10 parts by weight to 30 parts by weight of an A-B-A type block copolymer 2) 1 weight part of a water-absorbing polymer Parts to 10 parts by weight 3) Alicyclic petroleum resin 10 to 50 parts by weight 4) A combination with 10 to 50 parts by weight of a softening agent is essential, and this specific formulation allows ■ Softness that conforms to the skin. Adhesive properties - Absorbs sweat and secretions, and has adsorption properties, so it always adheres softly to the skin, does not pull the hair when peeled off, and also suppresses the appearance of stuffiness and sweating. Ta. This is truly an ideal pressure-sensitive adhesive composition.
次に上述の作用及び効果を実施例及び試験例により更に
詳しく説明する。Next, the above-mentioned functions and effects will be explained in more detail using Examples and Test Examples.
実施例I
A−B−A型ブロック共重合体として、カリフレックス
TR−1107(シェル化学製)25部と、脂環族系石
油樹脂としてアルコン(荒用化学製)40部、軟化剤と
して流動パラフィン30部をニーダ−にて150℃で混
練し、ついで吸水高分子としてサンウェットIM−30
0MPS (三洋化成製)5部を添加混合することによ
り本発明の粘着剤組成物を得た。Example I 25 parts of Cauliflex TR-1107 (manufactured by Shell Chemical Co., Ltd.) as an A-B-A type block copolymer, 40 parts of Alcon (manufactured by Arayo Chemical Co., Ltd.) as an alicyclic petroleum resin, and fluidized as a softener. 30 parts of paraffin was kneaded in a kneader at 150°C, and then mixed with Sunwet IM-30 as a water-absorbing polymer.
A pressure-sensitive adhesive composition of the present invention was obtained by adding and mixing 5 parts of 0MPS (manufactured by Sanyo Chemical).
実施例2
A−B−A型ブロック共重合体として、カリフレックス
TR−1107(シェル化学製)22部と、脂環族系石
油樹脂としてアル、コン(荒用化学製)42部、軟化剤
として流動パラフィン33部をニーグーにて160℃で
混練し、ついで吸水高分子としてアラソーブ800F
(荒用化学製)3部を添加混合することにより本発明の
粘着剤組成物を得た。Example 2 22 parts of Cauliflex TR-1107 (manufactured by Shell Chemical Co., Ltd.) as an A-B-A type block copolymer, 42 parts of Al, Con (manufactured by Arayo Chemical Co., Ltd.) as an alicyclic petroleum resin, and a softening agent. 33 parts of liquid paraffin was kneaded at 160°C in a Nigu machine, and then Arasorb 800F was mixed as a water-absorbing polymer.
(manufactured by Arayo Kagaku Co., Ltd.) by adding and mixing 3 parts to obtain the adhesive composition of the present invention.
実施例3
A−B−A型ブロック共重合体として、カリフレックス
TR−1111(シェル化学製)20部と、脂環族系石
油樹脂としてアルコン(荒用化学製)31部、軟化剤と
して流動パラフィン40部をニーグーにて160℃で混
練し、ついで酸化チタン3部と吸水高分子としてサンウ
ェットIM−300MPS(三洋化成製)6部を添加混
合することにより、本発明の粘着剤組成物を得た。Example 3 20 parts of Cauliflex TR-1111 (manufactured by Shell Chemical Co., Ltd.) as an A-B-A type block copolymer, 31 parts of Alcon (manufactured by Arayo Chemical Co., Ltd.) as an alicyclic petroleum resin, and fluid as a softener. The pressure-sensitive adhesive composition of the present invention is prepared by kneading 40 parts of paraffin at 160°C in a Nigu machine, and then adding and mixing 3 parts of titanium oxide and 6 parts of Sunwet IM-300MPS (manufactured by Sanyo Chemical) as a water-absorbing polymer. Obtained.
参考例1
実施例1で得た粘着剤組成物を、両輪方向にそれぞれ1
20%伸びるポリエステル不織布に、膜厚200μ」に
なるように展延し、医療用テーピングテープとした。Reference Example 1 One portion of the adhesive composition obtained in Example 1 was applied in the direction of both wheels.
It was spread on a 20% elongated polyester nonwoven fabric to a film thickness of 200 μ'' to make a medical taping tape.
参考例2
実施例2で得た粘着剤組成物を、60μ■の厚みでシリ
コーン処理された離型紙に展延し、ついで膜厚40/7
mのウレタンフィルムに圧着転写し、医療用サージカル
ドレッシングとした。Reference Example 2 The adhesive composition obtained in Example 2 was spread on silicone-treated release paper to a thickness of 60μ, and then the film thickness was 40/7.
This was transferred to a urethane film of 100 mm and used as a medical surgical dressing.
参考例3
実施例3で得た粘着剤組成物を、100−の厚みでシリ
コーン処理がされた離型紙に展延し、ついで発泡ポリブ
タジェンシートに圧着転写し、医療用サージカルテープ
とした。Reference Example 3 The adhesive composition obtained in Example 3 was spread on a release paper treated with silicone to a thickness of 100 mm, and then pressure-transferred onto a foamed polybutadiene sheet to obtain a medical surgical tape.
参考例4
実施例1で得た粘着剤組成物100部に、l−メントー
ル4.8部、サリチル酸メチル2.4部、ハツカ油1.
5部を添加し、シリコーン処理がされた離型紙に厚さ1
50μ鳳になるように展延し、ついでポリ塩化ビニルシ
ートに圧着転写し医療用貼付剤とした。Reference Example 4 To 100 parts of the adhesive composition obtained in Example 1, 4.8 parts of l-menthol, 2.4 parts of methyl salicylate, and 1.0 parts of peppermint oil were added.
Add 5 parts and apply 1 part to a thickness of silicone-treated release paper.
It was spread to a thickness of 50 μm and then transferred to a polyvinyl chloride sheet by pressure to prepare a medical patch.
参考例5
実施例1で得た粘着剤組成物100部に、2−メントー
ル5.4部、サリチル酸グリコール5.0部を添加し、
不織布に厚さ200μ職になるように展延し、医療用貼
付剤とした。Reference Example 5 To 100 parts of the adhesive composition obtained in Example 1, 5.4 parts of 2-menthol and 5.0 parts of glycol salicylate were added,
It was spread on a nonwoven fabric to a thickness of 200 μm to prepare a medical patch.
参考例6
実施例1で得た粘着剤組成物100部に、インドメタシ
ン3.5部を添加し、ポリ塩化ビニルシートに厚さ10
0μ鳳になるように展延し、医療用貼付剤とした。Reference Example 6 3.5 parts of indomethacin was added to 100 parts of the adhesive composition obtained in Example 1, and a polyvinyl chloride sheet was coated with a thickness of 10 parts.
It was spread to a thickness of 0μ and used as a medical patch.
参考例7
実施例2で得た粘着剤組成物100部に、ケトプロフェ
ン2部を添加し、シリコーン処理がされたポリエステル
フィルムに厚さ100μ麓になるように展延し、ついで
ポリエチレンフィルムに圧着転写し、医療用貼付剤とし
た。Reference Example 7 2 parts of ketoprofen was added to 100 parts of the adhesive composition obtained in Example 2, and the mixture was spread on a silicone-treated polyester film to a thickness of 100 μm, and then pressure-transferred onto a polyethylene film. It was made into a medical patch.
参考例8
実施例3で得た粘着剤組成物100部に、サリチル酸グ
リコール5部に溶解したケトプロフェン2.5部を添加
し、ポリエステルフィルムに厚さ100nになるように
展延し、医療用貼付剤とした。Reference Example 8 2.5 parts of ketoprofen dissolved in 5 parts of glycol salicylate was added to 100 parts of the adhesive composition obtained in Example 3, and the mixture was spread on a polyester film to a thickness of 100 nm and applied to a medical patch. It was used as a drug.
比較例I
A−B−A型ブロック共重合体として、カリフレックス
TR−1307(シェル化学製)25部と、脂環族系石
油樹脂としてアルコン(荒用化学製)40部、軟化剤と
して流動パラフィン30部をニーグーにて150℃で混
練し、ついでl−メントール4.5部、゛サリチル酸メ
チル2.3部、ハツカ油1.4部を添加後、参考例4と
同様に処理した。Comparative Example I 25 parts of Cauliflex TR-1307 (manufactured by Shell Chemical Co., Ltd.) as an A-B-A type block copolymer, 40 parts of Alcon (manufactured by Arayo Chemical Co., Ltd.) as an alicyclic petroleum resin, and fluid as a softener. 30 parts of paraffin were kneaded at 150 DEG C. in a Nigu machine, and then 4.5 parts of l-menthol, 2.3 parts of methyl salicylate, and 1.4 parts of peppermint oil were added, and the mixture was treated in the same manner as in Reference Example 4.
比較例2
A−B−A型ブロック共重合体として、カリフレックス
TR−1107(シェル化学製)25部と、ロジン系樹
脂40部、軟化剤として流動パラフィン30部をニーダ
−にて140℃で混練し、ついで!−メントール4.5
部、サリチル酸メチル2.3部、ハツカ油1.4部を添
加後、参考例4と同様に処理した。Comparative Example 2 25 parts of Cauliflex TR-1107 (manufactured by Shell Chemical) as an A-B-A type block copolymer, 40 parts of rosin resin, and 30 parts of liquid paraffin as a softener were mixed in a kneader at 140°C. Knead and then! -Menthol 4.5
After adding 2.3 parts of methyl salicylate and 1.4 parts of peppermint oil, the mixture was treated in the same manner as in Reference Example 4.
試験例1 (貼付試験)
健康成人男子35名の上背部に、本発明の実施例1より
得られた参考例4、及び参考例5、比較例1.2を用い
それぞれ4×6−のサイズのものを24時間貼付した。Test Example 1 (Patch Test) Reference Example 4 obtained from Example 1 of the present invention, Reference Example 5, and Comparative Example 1.2 were each applied to the upper backs of 35 healthy male adults in a size of 4 x 6-. was applied for 24 hours.
その結果を表1に示す。The results are shown in Table 1.
表1
■)皮膚刺激
24時間貼付後、試料を剥離し1時間後、24時間後の
皮膚の状態を観察し皮膚刺激を点数化した。(尚、評価
基準は下記の通りである。)判定 点数
変化なし 0
微弱な変化 ± 0.5
明瞭な変化 + 1.0
重篤な発赤 +1 2.0
2)剥離時の痛み
24時間貼付後、試料を剥離する際の皮膚、毛の引張り
具合を、剥離時の痛みで評価した。(尚、評価基準は下
記の通りである。)
痛くない ○
少し痛い △
皮膚・毛を引張り痛い ×
表1よりわかる通り、本発明より得られた参考例4、参
考例5は、吸水高分子を添加しない比較例1、他の樹脂
を添加した比較例2に比較、剥離時の痛みもなく、皮膚
刺激も非常に低いものであった。Table 1 ■) Skin irritation After application for 24 hours, the sample was peeled off, and the condition of the skin was observed 1 hour and 24 hours later, and the skin irritation was scored. (The evaluation criteria are as follows.) Judgment No change in score 0 Slight change ± 0.5 Clear change + 1.0 Severe redness +1 2.0 2) Pain when peeling off after 24 hours of application The tension of the skin and hair when the sample was peeled off was evaluated based on the pain during peeling. (The evaluation criteria are as follows.) Not painful ○ Slightly painful △ Painful when pulling skin and hair Compared to Comparative Example 1 in which no resin was added and Comparative Example 2 in which another resin was added, there was no pain during peeling and skin irritation was very low.
試験例2(吸水力試験)
本発明の実施例1.2及び比較例として、実施例1より
吸水高分子を除いた比較例3のそれぞれ10−のブロッ
クを用い試験を行った。Test Example 2 (Water Absorption Power Test) As Example 1.2 of the present invention and Comparative Example, a test was conducted using 10-blocks of Comparative Example 3 in which the water-absorbing polymer was removed from Example 1, respectively.
各ブロックを水中に浸し、8時間後に取り出しその重量
を測定し、増加した重量で除し吸水した量を表2に示す
。Each block was immersed in water, taken out after 8 hours, weighed, divided by the increased weight, and the amount of water absorbed is shown in Table 2.
表2
結果より明らかな如く、本発明の粘着剤組成物は、比較
例に比べきわだった吸水力を示した。Table 2 As is clear from the results, the adhesive composition of the present invention exhibited remarkable water absorption power compared to the comparative example.
〔発明の効果〕
前述の実施例、試験例の如く本発明の粘着剤組成物は、
1)A−B−A型ブロック共重合体
2)吸水高分子
3)脂環族系石油樹脂
4)軟化剤
との特定の組合せにより、
■皮膚に追従する柔らかい粘着特性
■汗、分泌物の吸収、及び吸着作用
等の特性を保持するため、絆創膏、サージカルドレッシ
ング、サージカルテープ、医療用貼付剤として気触れの
心配なく使用でき、又その機能を充分に発揮できるもの
であり、産業上非常に有用である。[Effects of the Invention] As shown in the above-mentioned Examples and Test Examples, the adhesive composition of the present invention comprises: 1) A-B-A type block copolymer 2) Water-absorbing polymer 3) Alicyclic petroleum resin 4) Due to a specific combination with an emollient, ■ Soft adhesive properties that follow the skin ■ Absorption of sweat and secretions, as well as adsorption properties, making it suitable for use as adhesive plasters, surgical dressings, surgical tapes, and medical patches. It can be used without worrying about problems, and its functions can be fully demonstrated, making it very useful industrially.
手続補正書、。発、
1.事件の表示
昭和63年 特許別箇129387号
2、発明の名称 粘着剤組成物3、補正をする
者
4、補正命令の日付 自発
5、補正の対象
(1) 明細書中、「3、発明の詳細な説明」の欄の
第7真上から第7行目の「アラソーブ800 FJの次
に「、アラソーブS−100Jを挿入する。Procedural Amendment,. From, 1. Indication of the case 1988 Patent Separate Section No. 129387 2, Title of the invention Adhesive composition 3, Person making the amendment 4, Date of amendment order Voluntary action 5, Subject of amendment (1) In the specification, "3. Insert "Arasorb S-100J" next to "Arasorb 800 FJ" in the 7th line from the top of the "Detailed Description" column.
(2)同書中、第8頁上から第13行目の「経皮吸収製
薬物」を「経皮吸収性薬物jと訂正する。(2) In the same book, in the 13th line from the top of page 8, "transdermal drug" is corrected to "transdermal drug j."
(3)同書中、第14真上から第7行目の次に、「尚、
下記の実施例1〜4及び比較例1〜2の各成分の使用に
おける部は重量部を意味する。jを挿入する。(3) In the same book, after the 7th line from the top of the 14th line, it says, ``In addition,
In the use of each component in Examples 1 to 4 and Comparative Examples 1 to 2 below, parts refer to parts by weight. Insert j.
(4)同書中、第14真上から第11行目の「アルコン
」を「アルコンP 1001と訂正する。(4) In the same book, "Arcon" in the 11th line from just above the 14th line is corrected to "Arcon P 1001."
(5)同書中、第15真上から第2行目の「アルコン」
を「アルコンP 100Jと訂正する。(5) “Archon” in the second line from the top of No. 15 in the same book
"Corrected to "Arcon P 100J.
(6)同書中、第15真上から第11行目の「アルコン
」を「アルコンP−85Jと訂正する。(6) In the same book, "Arcon" in the 11th line from just above the 15th line is corrected to "Arcon P-85J."
(7)同書中、第15頁下から第3行目の次に、下記の
「実施例4」を新たに挿入する。(7) In the same book, the following "Example 4" is newly inserted after the third line from the bottom of page 15.
「実施例4
A−B−A型ブロック共重合体として、カリフレックス
TR−1107(シェル化学型)24部と、脂環族系石
油樹脂としてアルコンP−85(荒用化学製)35部、
軟化剤として流動パラフィン35部をニーダ−にて15
0℃で混練し、ついで酸化チタン3部と吸水高分子とし
てサンウェットIM−1000MPS (三洋化成製)
3部を添加混合することにより、本発明の粘着剤組成物
を得た。」"Example 4 24 parts of Cauliflex TR-1107 (Shell chemical type) as an A-B-A type block copolymer, 35 parts of Alcon P-85 (manufactured by Arayo Kagaku) as an alicyclic petroleum resin,
Add 35 parts of liquid paraffin as a softener to 15 parts in a kneader.
Knead at 0°C, then add 3 parts of titanium oxide and Sanwet IM-1000MPS (manufactured by Sanyo Chemical) as a water-absorbing polymer.
By adding and mixing 3 parts, a pressure-sensitive adhesive composition of the present invention was obtained. ”
Claims (1)
量部と脂環族系石油樹脂10重量部〜50重量部、軟化
剤10重量部〜50重量部及び吸水高分子1重量部〜1
0重量部より構成される粘着剤組成物。1. 10 to 30 parts by weight of A-B-A type block copolymer, 10 to 50 parts by weight of alicyclic petroleum resin, 10 to 50 parts by weight of softener, and 1 part by weight of water-absorbing polymer ~1
An adhesive composition composed of 0 parts by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63129387A JPH0736835B2 (en) | 1988-05-25 | 1988-05-25 | Adhesive composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63129387A JPH0736835B2 (en) | 1988-05-25 | 1988-05-25 | Adhesive composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01297069A true JPH01297069A (en) | 1989-11-30 |
JPH0736835B2 JPH0736835B2 (en) | 1995-04-26 |
Family
ID=15008321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63129387A Expired - Lifetime JPH0736835B2 (en) | 1988-05-25 | 1988-05-25 | Adhesive composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0736835B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0483370A1 (en) * | 1990-05-17 | 1992-05-06 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneous preparation containing estradiol |
JPH08319234A (en) * | 1995-05-24 | 1996-12-03 | Yuutoku Yakuhin Kogyo Kk | Percutaneous absorption type antiinflammatory and analgesic plaster |
JP2000178186A (en) * | 1998-10-05 | 2000-06-27 | Yuutoku Yakuhin Kogyo Kk | Percutaneous absorption tape preparation |
US6262121B1 (en) | 1997-07-18 | 2001-07-17 | Teikoku Seiyaku Co., Ltd. | Oily patches for external use containing diclofenac sodium |
US6953590B1 (en) | 1998-10-05 | 2005-10-11 | Yutoku Pharmaceutical Ind. Co., Ltd. | Tape material for transcutaneous absorption |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS602253A (en) * | 1983-06-20 | 1985-01-08 | 帝国製薬株式会社 | Tape-shaped water-containing sticking agent and production thereof |
-
1988
- 1988-05-25 JP JP63129387A patent/JPH0736835B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS602253A (en) * | 1983-06-20 | 1985-01-08 | 帝国製薬株式会社 | Tape-shaped water-containing sticking agent and production thereof |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0483370A1 (en) * | 1990-05-17 | 1992-05-06 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneous preparation containing estradiol |
JPH08319234A (en) * | 1995-05-24 | 1996-12-03 | Yuutoku Yakuhin Kogyo Kk | Percutaneous absorption type antiinflammatory and analgesic plaster |
US6262121B1 (en) | 1997-07-18 | 2001-07-17 | Teikoku Seiyaku Co., Ltd. | Oily patches for external use containing diclofenac sodium |
JP2000178186A (en) * | 1998-10-05 | 2000-06-27 | Yuutoku Yakuhin Kogyo Kk | Percutaneous absorption tape preparation |
US6953590B1 (en) | 1998-10-05 | 2005-10-11 | Yutoku Pharmaceutical Ind. Co., Ltd. | Tape material for transcutaneous absorption |
Also Published As
Publication number | Publication date |
---|---|
JPH0736835B2 (en) | 1995-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3179989B1 (en) | Silicone-containing acrylic polymers for transdermal drug delivery compositions | |
JP4705301B2 (en) | Patch | |
JP5044078B2 (en) | UV shielding patch | |
KR100363052B1 (en) | Percutaneous device containing polyvinylpyrrolidone as a dissolution enhancer | |
JP4346696B2 (en) | Transdermal therapeutic device | |
EP1121941B1 (en) | Sorbefacients and preparations for percutaneous absorption containing the same | |
WO2001052823A2 (en) | Compositions to effect the release profile in the transdermal administration of drugs | |
WO2002032431A1 (en) | Compositions for external preparations | |
WO2005025549A2 (en) | Multi-layer transdermal drug delivery device | |
JP3466305B2 (en) | Dissolving agent and external preparation containing the dissolving agent | |
WO1999036061A1 (en) | Plasticizer and patch containing the plasticizer | |
JP4468669B2 (en) | Hypoallergenic patch | |
JP3144895B2 (en) | Medical adhesive tape or sheet | |
JPH01297069A (en) | Tacky adhesive agent composition | |
JP6867210B2 (en) | Patch | |
JPH08310946A (en) | Percutaneous absorbable pharmaceutical preparation | |
JP4167750B2 (en) | Transdermal absorption base and percutaneous absorption preparation containing the base | |
JP3525272B2 (en) | Skin sticking sheet | |
JP3199770B2 (en) | Patch for transdermal administration and method for producing the same | |
JP2632838B2 (en) | External patch | |
JPH01297059A (en) | Warm heat sticking agent | |
JP3461401B2 (en) | Transdermal tape | |
JP2933623B2 (en) | External patch for deprodone propionate | |
JPH0714866B2 (en) | Transdermal patch | |
JPH09194349A (en) | Sheet for skin strap |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090426 Year of fee payment: 14 |